Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08SHE
|
||||
| Former ID |
DNCL003104
|
||||
| Drug Name |
SEP-228432
|
||||
| Indication | Depressive disorders; Neuropathic pain [ICD9: 296, 710.0, 356.0, 356.8; ICD10:F30-F39, M32, G64, G90.0] | Phase 1 | [523795] | ||
| Company |
Sunovion Pharmaceuticals
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent serotonin transporter | Target Info | Inhibitor | [548778] | |
| KEGG Pathway | Serotonergic synapse | ||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| References | |||||
| Ref 523795 | ClinicalTrials.gov (NCT01531972) A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.